Le Fur G, Meininger V, Baulac M, Phan T, Uzan A
Rev Neurol (Paris). 1981;137(2):89-96.
(3H) spiroperidol binding has been measured in lymphocytes from patients with Parkinson's disease and age matched healthy volunteers. A dramatic decrease (73 p. 100) in the number of binding sites Bmax without any variation of the affinity KD has been observed in untreated Parkinsonian patients. This decrease in Bmax is linearly correlated with the degree of disability of the Parkinsonian patients (r = 0.891, p less than 0.001). This decrease appeared to be relatively selective since no variation was observed with patients suffering of other neurological disorders. The possible relationships with the number of striatal dopamine receptors are discussed. With levodopa therapy, Bmax had the same mean value as in control subjects. This result means that levodopa induces an increase in lymphocyte binding sites and in five patients this increase could be observed by study before and during drug administration. In some severely disabled patients who had received levodopa for several years, Bmax was found much lower or higher than the mean value, which may suggest different interpretations of drug unefficiency.
已对帕金森病患者及年龄匹配的健康志愿者的淋巴细胞进行了（3H）螺哌啶结合检测。在未经治疗的帕金森病患者中，观察到结合位点数量Bmax显著减少（73%），而亲和力KD没有任何变化。Bmax的这种减少与帕金森病患者的残疾程度呈线性相关（r = 0.891，p < 0.001）。这种减少似乎具有相对选择性，因为患有其他神经系统疾病的患者未观察到变化。文中讨论了其与纹状体多巴胺受体数量的可能关系。接受左旋多巴治疗后，Bmax的平均值与对照组受试者相同。这一结果意味着左旋多巴可诱导淋巴细胞结合位点增加，并且在5名患者中，在给药前和给药期间的研究中均可观察到这种增加。在一些接受左旋多巴治疗数年的严重残疾患者中，发现Bmax远低于或高于平均值，这可能提示对药物无效有不同的解释。
